Acrivon Therapeutics Inc (ACRV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.13+3.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACRV
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 57.4 | 60.0 | 64.0 | 46.0 | 23.9 | — | — |
| Operating Income | (78.4) | (84.1) | (89.2) | (67.1) | (32.7) | (16.2) | — |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | — | — | — | 7.0 | 1.5 | — | — |
| Other Non-Operating Income / Expenses | 4.1 | 6.2 | 8.6 | 6.7 | 1.5 | (0.1) | — |
| EBT, Incl. Unusual Items | — | (77.8) | — | — | — | — | — |
| Net Income | |||||||
| Net Income | (74.2) | (77.9) | (80.6) | (60.4) | (31.2) | (16.2) | — |
| Per Share | |||||||
| Basic EPS | (1.77) | (2.02) | (2.38) | (2.74) | (7.56) | (9.32) | — |
| Diluted EPS | (1.77) | (2.02) | (2.38) | (2.74) | (7.56) | (9.32) | — |
| Basic Weighted Avg Shares | 41.8 | 38.5 | 33.8 | 22.1 | 4.1 | 1.7 | — |
| Diluted Weighted Avg Shares | 41.8 | 38.5 | 33.8 | 22.1 | 4.1 | 1.7 | — |
| Supplemental | |||||||
| EBIT | (78.4) | (84.1) | (89.2) | (67.1) | (32.7) | (16.2) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.